Minaris Regenerative Medicine Japan News and Activities

Minaris Regenerative Medicine Japan is owned by Altaris. Altaris has a direct presence in 2 countries.

Altaris has 9 subsidiaries including Analogic, Kindeva Drug Delivery and Minaris Advanced Therapies.

They are in:

• Pharmaceuticals40%
• Healthcare20%
• Other40%

View the org chart displaying its 5 main executives

Most searched biographies at Minaris Regenerative Medicine Japan

• Takuya Muramoto, General Manager
• Hiroto Bando, President
• Shinobu Kuwae, Chief Technology Officer

Popular executive movements at Altaris

• Dorothy Sandberg has joined the company as Vice President, Human Resources and Talent Development  (posted on October 20 2025).

Create your alert
to follow the executive moves at Minaris Regenerative Medicine Japan.

Altaris has 1,920 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Vertex Pharmaceuticals has announced the acquisition of Crinetics Pharmaceuticals  (posted on July 7 2026).
• Novartis has announced the acquisition of Myricx Bio  (posted on July 6 2026).
• Ipsen has announced the acquisition of Kartos Therapeutics  (posted on July 3 2026).

Popular contacts in Pharmaceuticals

• David Ricks - President, Chief Executive Officer and Chairman of the Board at Eli Lilly
• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz

Learn more about the Pharmaceuticals industry

Press releases by Minaris Regenerative Medicine Japan

Social media about Minaris Regenerative Medicine Japan

• Minaris Regenerative Medicine Japan on Wikipedia, Google News & Yahoo Finance
• Minaris Regenerative Medicine Japan on LinkedIn, X (Twitter) & YouTube